Table 2.

Summary of G1m3-trastuzumab and G1m1,17-trastuzumab specific T-cell proliferation and IL-2 ELISpot responses in the homozygous G1m3 and G1m1,17 donor cohorts. Frequency (expressed as a percentage of the donor cohort) of positive proliferation responses (SI ≥ 1.9, significant p < 0.05) and IL-2 responses (SI ≥ 1.9, significant p < 0.05).

Donors	Homozygous G1m3		Homozygous G1m1,17
Sample	G1m3 Trastuzumab	G1m1,17 Trastuzumab	G1m3 Trastuzumab	G1m1,17 Trastuzumab
% Proliferation	5%	5%	6%	6%
% ELISpot	5%	5%	6%	6%
% Proliferation and ELISpot	5%	5%	6%	3%